SAN FRANCISCO and LOS ANGELES, March 17, 2025 /PRNewswire/ — Alife Health, a leader in AI-driven tools designed to enhance the in-vitro fertilization (IVF) process, has expanded its partnership with US Fertility, the largest network of physician-owned fertility practices in the United States. This collaboration will provide IVF patients with personalized, AI-powered laboratory summary reports, including embryo images, lab-generated grading, clinical insights, and next steps. This marks a significant step forward in integrating AI technology into reproductive healthcare, reinforcing US Fertility’s leadership in innovation and Alife’s position as a premier provider of AI solutions for IVF.
With a network of over 100 clinics and 32 IVF laboratories across the U.S., US Fertility serves tens of thousands of patients annually. The nationwide implementation of Alife’s technology is a key part of the organization’s ongoing commitment to improving the precision, efficiency, and consistency of IVF procedures, ensuring that each patient receives personalized and high-quality care.
“Partnering with Alife represents a major leap for US Fertility,” said Richard Jennings, CEO of US Fertility. “Alife’s embryo imaging technology delivers detailed reports directly to patients, facilitating engagement with the IVF process. By integrating AI, we are setting a new standard for IVF delivery, streamlining clinical workflows, and improving patient experiences across our national network.”
Alife’s Embryo Assist™ tool simplifies and digitizes the traditional manual process of embryo grading. With seamless microscope integration and real-time connection to electronic medical records (EMR), the software enables embryologists to capture, rank, and organize embryo data in one place. This reduces the time spent on manual documentation, saving up to 15 minutes per cycle per embryologist. Additionally, the software provides real-time lab updates, allowing embryologists to make faster, more informed decisions. Personalized embryo reports are also generated for patients, giving them clear, data-driven insights into their IVF journey and enhancing their understanding of the process.
Dr. Kate Devine, Medical Director and Chief Research Officer of US Fertility, said, “The integration of Alife’s AI-driven embryo vitrification reporting marks an exciting development for US Fertility. We’ve already seen how it boosts operational efficiencies and improves the patient experience.”
Melissa Teran, CEO of Alife, shared her excitement about the partnership: “This collaboration with US Fertility is a gamechanger for the fertility industry. As the largest network in the field, US Fertility’s adoption of our technology is a tremendous endorsement of Alife’s approach to IVF. We are thrilled to help optimize their embryology reporting and enhance patient care.”
The nationwide implementation of Alife’s technology by US Fertility signals a new era of efficiency, precision, and data-driven decision-making in fertility labs, advancing the IVF process on a large scale.
Related topics:
Infertility Treatment Devices Market Poised for Significant Growth by 2032
Congressman Mike Lawler Reintroduces Legislation to Expand IVF Access for New York Families
The Hidden Lives of Frozen Embryos: A Growing Trend in Adoption
